Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: DaVita is a leading provider of dialysis services and related products. The company operates a large network of dialysis centers and manages joint ventures. The reporting period covers the first quarter of 2007, comparing results to the same period in 2006 and the preceding quarter.
Key Financial Metrics
| Metric (in thousands) | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Operating Revenues | $1,278,166 | $1,163,188 |
| Operating Income | $193,317 | $162,075 |
| Net Income | $76,582 | $57,469 |
| Diluted EPS | $0.72 | $0.55 |
| Operating Cash Flow | $88,031 | $(23,564) |
| Total Debt (Long-term + Current) | $3,755,506 | $3,751,251 |
| Cash and Cash Equivalents | $356,384 | $279,146 |
Margins: Operating margin for Q1 2007 was approximately 15.1% ($193.3M / $1,278.2M). Patient care costs represented 69.0% of total operating revenues.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased by 9.9% ($115 million) compared to Q1 2006. This was driven by a 5.4% increase in the number of dialysis treatments and a 3.4% increase in average revenue per treatment.
- Profitability: Operating income rose 19.3% to $193.3 million. Net income increased 33.3% to $76.6 million, primarily due to higher operating income and a reduction in debt expense.
- Cash Flow: Operating cash flow turned positive at $88.0 million, a significant improvement from the $(23.6) million outflow in Q1 2006. The prior year's outflow was heavily impacted by an $85 million income tax payment related to divestitures.
- Debt Structure: The company issued $400 million in 6 5/8% senior notes in February 2007 and used proceeds to pay down Term Loan B. Interest rate margins on Term Loans A and B were reduced, lowering the overall effective interest rate.
- Accounts Receivable: Days Sales Outstanding (DSO) improved from 70 days to 66 days due to better cash collection performance.
Guidance, Outlook, and Risks
Guidance and Outlook
- 2007 Operating Income: Revised upward to a range of $740 million to $780 million (previously $700-$760 million).
- 2007 Operating Cash Flow: Projected to be between $460 million and $510 million.
- Capital Expenditures: Expected to spend $110-$120 million on maintenance/IT and $200-$220 million on new center development and acquisitions.
- 2008 Outlook: Management expects 2008 operating income to be in the same range as the revised 2007 guidance, anticipating potential private rate compression.
Risks and Contingencies
- Government Investigations: The company is cooperating with multiple U.S. Attorney investigations (Eastern District of Missouri, Eastern District of New York, and Eastern District of Texas) regarding billing practices, EPO utilization, and relationships with physicians. While no proceedings have been initiated, negative findings could result in substantial penalties or exclusion from Medicare/Medicaid.
- Regulatory Changes: Risks include potential reductions in Medicare/Medicaid payment rates, changes to the ESRD composite rate, and increased scrutiny of EPO administration following FDA labeling changes.
- Commercial Payor Rates: Approximately 35% of revenue comes from commercial payors. Consolidation among payors and downward pressure on rates pose a risk to future margins.
- Pharmaceutical Costs: EPO and other pharmaceuticals account for a significant portion of revenue and costs. Pricing changes by suppliers (e.g., Amgen) or shifts in clinical practice patterns could materially impact results.
Investor Verification Checklist
- Debt Covenants: Verify compliance with financial covenants in the Senior Secured Credit Facilities, particularly the leverage ratio thresholds that affect share repurchase and dividend limitations.
- Investigation Status: Monitor updates on the U.S. Attorney investigations in Missouri, New York, and Texas for any escalation to formal charges or settlements.
- Commercial Rate Trends: Track the mix of commercial vs. government payors and the outcome of contract negotiations to assess the risk of rate compression.
- EPO Utilization: Review changes in EPO prescribing patterns and reimbursement policies following the FDA black box warning and CMS policy shifts.
- Integration Progress: Assess the successful integration of DVA Renal Healthcare's billing and clinical systems to ensure no material adverse impact on collections or compliance.